Alaunos appoints new director, cash runway into Q3 2024, plans reverse stock split

Alaunos Therapeutics, Inc.

Dale Curtis Hogue, Jr. appointed independent director effective Dec 29, 2023; receives initial 150k option grant vesting over 36 months.
Cash resources expected to fund operations into Q3 2024 due to cost-saving measures.
Company taking steps to implement reverse stock split approved by stockholders in June 2023.
No assurance reverse split will increase stock price or cure Nasdaq listing deficiencies.

item 5.02 item 7.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dale Curtis Hogue, Jr.

director

TCRT · Alaunos Therapeutics, Inc.

Effective: 2023-12-29
Filed: January 2, 2024, 6:59 PM ET

On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dale Curtis Hogue, Jr. was appointed as director at Alaunos Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On December 29, 2023, the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) appointed Dale Curtis Hogue, Jr. as a director of the Company, effective immediately.

View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-000240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.